Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IO-312
- Development stage
- Unknown
- Lead developer
- Immune-Onc Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IO-312 is a first-in-class bispecific monoclonal antibody engineered to target LILRB4 (also known as ILT3) and CD3. Developed by Immune-Onc Therapeutics, it is designed for the treatment of acute myeloid leukemia (AML) and other hematologic malignancies. The drug binds with high affinity to LILRB4 and with low affinity to CD3, aiming to maximize anti-tumor effects while minimizing cytokine release-related toxicities. Preclinical data demonstrate potent and specific killing of monocytic AML cells both in vitro and in vivo. IO-312’s design allows for efficient manufacturing and cross-reactivity with non-human primate targets, supporting preclinical toxicology studies[1][3].
- Other names
- LILRB4 × CD3 bispecific antibodyLILRB4 x CD3LILRB-4 x CD3LILRB 4 x CD3ILT3 x CD3ILT-3 x CD3ILT 3 x CD3
02
Targets
LILRB4CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on IO-312.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IO-312.